Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe
Oslo, 24 June 2024 - Navamedic ASA and Orion Corporation (“Orion”) have today signed a license and supply agreement for Flexilev®, including the OraFID® dispenser, across Europe, not including Sweden, Norway, Denmark, and Iceland, where Navamedic will market and sell the product. Flexilev is a novel prescription treatment for Parkinson’s disease and was added to Navamedic’s product portfolio following the acquisition of Sensidose AB in May 2023. Through the signed agreement, Orion has been granted the exclusive right to market, distribute, and sell Flexilev® in 27 countries in Europe,